NCT04624230进行中（未招募）3 期
OPEN-LABEL INDUCTION AND MAINTENANCE STUDY OF ORAL CP-690,550 (TOFACITINIB) IN CHILDREN WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- Pfizer
- 入组人数
- 118
- 试验地点
- 132
- 主要终点
- Remission by central read Mayo score following 44 weeks in the maintenance phase.
研究概览
简要总结
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients with prior TNFi failure or intolerance will be enrolled. Outside of the US or EU, patients having had inadequate response or intolerance to oral or IV corticosteroids or azathioprine or 6-mercaptopurine or TNFi will be enrolled.
All eligible participants will initially receive open label tofacitinib at a dose expected to produce equivalent systemic exposure to that observed in adults receiving 5 mg BID with the option for individual dose increase to 10 mg BID adult dose equivalent if dose escalation criteria are met.
The primary objective of this study is to evaluate the efficacy of tofacitinib based on remission in pediatric participants with moderately to severely active UC. The primary endpoint is remission by central read Mayo score following 44 weeks in the maintenance phase. Remission is defined by a Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0.
The study Design is an open-label Phase 3 study that includes a screening period of up to 4-weeks duration, an 8-week or 16-week induction phase, a 44-week maintenance phase, and a 24-month extension phase for pediatric participants with moderately to severely active UC. Participants will have a follow-up visit 4 weeks after the last dose of study intervention and a telephone contact 8 weeks later to assess for any adverse events (AEs)/serious adverse events (SAEs). The total maximum duration of this study will be up to 180 weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Evidence of a personally signed and dated informed consent document and assent document.
- •Males and females 2 to less than18 years old and weighing at least 10 kg.
- •Having a pathology report that confirms colonic inflammation consistent with UC with a clinical diagnosis of UC for at least 12 weeks prior to baseline, with biopsy report supporting the diagnosis of UC.
- •Participants diagnosed with UC at age less than 6 years old, must have had testing and be negative for monogenic disorders associated with very early onset IBD.
- •Moderately to severely active UC as defined (via screening colonoscopy) by a Mayo score of at least 6, with a rectal bleeding score of at least 1 and an endoscopic subscore of at least
- •Pediatric Ulcerative Colitis Activity Index (PUCAI) score greater or equal to 35 .
- •No history of dysplasia or colon cancer.
- •No evidence or history of untreated or inadequately treated active or latent infection with Mycobacterium Tuberculosis.
- •For participants outside of the United States or the European Union: have had an inadequate response or been intolerant to at least one prior therapy as listed below or have a medical contraindication to such therapies:
- •Oral or intravenous (IV) corticosteroids;
- •Azathioprine or 6-mercaptopurine;
- •TNF inhibitors or anti integrin therapy.
- •For participants in the United States and the European Union: have had an inadequate response or intolerance to TNF inhibitors.
- •Stable doses of the following therapies for UC:
- •Oral 5 Aminosalicyclic acids (ASA) or sulfasalazine
- •Oral corticosteroids equivalent to prednisone at most 1 mg/kg up to a maximum of 20 mg/day or budesonide up to 9 mg/day.
- •female participant is eligible if she is not pregnant or breastfeeding, If she is a woman of child bearing potential, she needs to be using a contraceptive method that is highly effective (with a failure rate of <1% per year).
排除标准
- •Diagnosis of indeterminate colitis, isolated proctitis, microscopic colitis, infectious colitis, Crohn's disease, or clinical findings suggestive of Crohn's disease.
- •History of symptomatic obstructive intestinal strictures or active ostomy, or history of colectomy, extensive small bowel resection ( greater than100 centimetres) or short bowel syndrome, or hospitalization for UC related reason(s) within 2 weeks of baseline visit.
- •Any factors or clinical characteristics potentially related to the risk of venous thromboembolism that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •Participants who have previously received tofacitinib or another Janus Kinase inhibitor.
- •Vaccination or exposure to a live or attenuated vaccine within the 6 weeks prior to the first dose of study drug, or who are expected to be vaccinated or to have household exposure to these vaccines during treatment or during the 6 weeks following discontinuation of study drug.
- •Participants having received azathioprine, 6-mercaptopurine, methotrexate, thioguanine, infliximab, adalimumab, golimumab, ustekinumab, interferon, cyclosporine, mycophenolate, tacrolimus, IV or rectally administered corticosteroids, natalizumab, vedolizumab, other antiadhesion molecules, or investigational drugs during the specified time periods prior to baseline whereby they may still have pharmacokinetic and/or pharmacodynamic effect in the body of the participant.
- •Previous treatment by leukocyte apheresis including selective lymphocyte, monocyte, or granulocyte apheresis, or plasma exchange within 6 months prior to baseline.
- •Treatment by specified prohibited concomitant medications, including moderate to potent CYP3A inducers or inhibitors in the specified time periods prior to the first dose of study drug or are expected to receive any of these medications during the study period.
- •Chronic and frequent use of antimotility agents for control of diarrhea (ie, diphenoxylate hydrochloride with atropine sulfate or loperamide).
- •History of bowel surgery, including cholecystectomy within 6 months prior to baseline, history of appendectomy within 3 months prior to baseline, or significant trauma or major surgery within 4 weeks of screening visit are excluded.
- •Participants with the following laboratory values at screening:
- •Hemoglobin level lower than 9.0 g/Dl.
- •Absolute white blood cell (WBC) count lower than 3000/mm
- •Absolute neutrophil count lower than 1200/mm
- •Absolute lymphocyte count lower than 750/mm
- •Thrombocytopenia as defined by a platelet count lower than 100,000/mm
- •Estimated bedside Schwartz Glomerular filtration rate (GFR) lower or equal to 40 mL/min/1.73 m
- •Total bilirubin, aspartate aminostransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal.
- •Positive stool examinations for enteric pathogens, pathogenic ova or parasites, or C. difficile toxin at screening.
- •Participants infected with human immunodeficiency virus (HIV) or hepatitis B or C viruses.
- •History of more than one episode of HZ, a history of disseminated HZ or disseminated herpes simplex.
- •History or current symptoms of any lymphoproliferative disorder (eg, Epstein Barr Virus (EBV) related lymphoproliferative disorder, lymphoma, leukemia, myeloproliferative disorders, multiple myeloma, or signs and symptoms suggestive of currently lymphatic disease).
- •Clinically significant infections currently or within 3 months prior to baseline (eg, those requiring hospitalization or parenteral antimicrobial therapy or opportunistic infections), a history of any infection requiring antimicrobial therapy within 2 weeks of baseline, or a history of any infection otherwise judged by the investigator to have the potential for exacerbation by participation in the study.
- •Any malignancies or with a history of malignancies, with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin.
- •Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are employees of the Sponsor, including their family members, directly involved in the conduct of the study.
- •Participation in other studies involving investigational drug(s) within 2 months prior to study entry and/or during study participation.
- •Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or study intervention administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •Pregnant female participants; breastfeeding female participants; fertile female participants of childbearing potential who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and through the telephone follow up visit.
- •History of allergies, intolerance or hypersensitivity to lactose or tofacitinib, or any other excipients of the investigational medicinal products, including placebos.
研究组 & 干预措施
tofacitinib
Experimental
Open label tofacitinib 5 mg BID weight based adult equivalent with the option for individual dose increase to 10 mg BID weight based adult equivalent for a limited time if dose escalation criteria are met, prior to returning to 5 mg BID.
干预措施: tofacitinib (Drug)
结局指标
主要结局
Remission by central read Mayo score following 44 weeks in the maintenance phase.
时间窗: Outcome measured at the end of the 44 weeks of the maintenance phase.
Remission is defined by central endoscopy read Mayo score of 2 points or lower, with no individual subscore exceeding 1 point and a rectal bleeding subscore of 0. The primary outcome Mayo score is the summation of 4 subscores as listed below : * patient reported stool frequency (scored 0 to 3) * patient reported rectal bleeding (scored 0 to 3) * central read findings on endoscopy (scored 0 to 3) * physician's global assessment (scored 0 to 3) The Mayo score has a scale from 0 to 12 points, with the lower score indicating lower ulcerative colitis (UC) disease activity.
次要结局
- Change from baseline in fecal calprotectin levels(Outcome measured through study completion, an average of 3 and a half years)
- Response by Mayo score(Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44)
- Remission by Mayo score(Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44)
- Change from baseline in Mayo score.(Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44)
- Response measured by Partial Mayo Score(Outcome measured through study completion, an average of 3 and a half years)
- Peak (maximum) plasma concentration of tofacitinib (Cmax)(Outcome measured at baseline, induction Week 8, induction Week 16, maintenance Week 16, maintenance Week 44)
- Change from baseline in Partial Mayo score(Outcome measured through study completion, an average of 3 and a half years)
- Response by PUCAI score(Outcome measured through study completion, an average of 3 and a half years)
- Change from baseline in PUCAI score(Outcome measured through study completion, an average of 3 and a half years)
- Percentage of Participants Achieving Endoscopic Improvement at Week 8, 16, and 44(Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44)
- Time to flare(Outcome measured from 2 to 4 months in the study, through study completion, an average of 3 and a half years)
- Change from baseline in serum high sensitivity C-Reactive Protein (hsCRP) levels(Outcome measured through study completion, an average of 3 and a half years)
- Corticosteroid free remission by Partial Mayo Score(Outcome measured through study completion, an average of 3 and a half years)
- Average plasma concentration of tofacitinib (Cavg)(Outcome measured at baseline, induction Week 8, induction Week 16, maintenance Week 16, maintenance Week 44)
- Evaluation of taste acceptability of tofacitinib oral solution, and acceptability of film coated tablet by choosing one of 5 choices(Outcome measured at induction week 2)
- Percentage of Participants Achieving Endoscopic Remission at Week 8, 16, and 44(Outcome measured at induction Week 8, induction Week 16, and maintenance Week 44)
- Remission by PUCAI score(Outcome measured through study completion, an average of 3 and a half years)
研究者
研究点 (132)
Loading locations...
相似试验
进行中（未招募）
1 期
A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS ⅡMucopolysaccharidosis IIHunter SyndromeNCT05422482GC Biopharma Corp12
撤回
1 期
Investigation of Oral OKN-007 in Recurrent High-grade Glioma ParticipantsOligodendrogliomaGlioblastomaAstrocytomaNCT03649464Oblato, Inc.
终止
2 期
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal TransplantationKidney TransplantationNCT06365437ITB-Med LLC33
已完成
2 期
A Dose Escalation Study in de Novo Renal TransplantationKidney TransplantationNCT04311632ITB-Med LLC13
已完成
2 期
Open Label Arimidex in GynecomastiaGynecomastiaNCT00241436AstraZeneca35